News
Academy
Publications
All PublicationsE-Books
Media
Editorial PodcastsEditorial VideosPeer ExchangePractice AcademySponsored PodcastsSponsored Videos
More
Conferences
Conference CoverageConference Listing
Columns
All ColumnsA Closing ThoughtClinical Trial InsightsView from BrusselsView from Washington
Resources
AdvertiseBlogsEventsFront & CenterPartner PerspectivesWhite Papers
Webcasts

Subscribe

  • News
  • Academy
  • Publications
  • Media
  • Conferences
  • Columns
  • Resources
  • Webcasts
  • Subscribe
  • Clinical Operations & Strategy
    • Decentralized Clinical Trials
    • Trial Design
    • Investigative Sites
    • CRO/Sponsor
    • Risk-Based Monitoring
    • Protocol Design
    • Clinical Trial Supply Chain
    • Study Start-Up
    • Early Phase Development
  • DEI
    • Industry Initiatives
    • Diversity Action Plans
    • Recruitment
  • Data Management
    • Analytics
    • Electronic Data Capture
    • Real World Evidence
    • Metrics & Benchmarks
  • Patient Participation
    • Integrated Research
    • CRAACO
    • Enrollment
  • Regulatory
    • Institutional Review Board & Ethics Committee
    • FDA
    • EMA
  • Technology
    • Artificial Intelligence/Machine Learning
    • eClinical
    • mHealth
Spotlight -
CNS Drug Development Resources|
Conference Coverage|
Peer Exchange|
DE&I|
Editorial Videos
Advertisement

Burkhard Breuer, PhD

Advertisement

Articles by Burkhard Breuer, PhD

table1.png

RBM—An Update of Experiences Among European CRAs

ByChristine Künzl, PhD,Burkhard Breuer, PhD,Yvonne Rollinger, PhD,Michael Sigmund,Veronika Kunert
October 20th 2017

An RBM survey conducted in 2014 was repeated in 2016 in order to find out, how knowledge and practical experience with RBM have changed over that time period.

Advertisement

Latest Updated Articles

  • table1.png
    RBM—An Update of Experiences Among European CRAs

    Published: October 20th 2017 | Updated:



Advertisement
Advertisement

Trending on Applied Clinical Trials Online

1

Thermo Fisher, Lundbeck Announce New OpenAI Partnerships Advancing AI in Drug Development

2

Using Global Patient Data to Design Smarter, More Inclusive Clinical Trials

3

ACT Brief: AI Partnerships, Data-Driven Site Activation, and FDA Approval for Omvoh’s Single-Injection Regimen

4

Imfinzi Regimen Demonstrates 22% Survival Benefit in Early Gastric and GEJ Cancer

5

ACT Brief: AI Expands Global Site Leadership as Ozempic Shows Potential to Reverse Biological Age

  • About
  • Advertise
  • Contact Us
  • Editorial Contacts
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

  • Applied Clinical Trials
  • BioPharm International
  • Cannabis Science and Technology
  • Chromatography Online
  • Nutritional Outlook
  • Pharmaceutical Commerce
  • Pharmaceutical Executive
  • Pharm Tech
  • Spectroscopy Online
  • Turbo Machinery Magazine
IS1
Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us